

IMLYGIC® ▼  
(talimogene laherparepvec)

## PATIENT ALERT CARD

**Please carry this card  
with you at all times.**

Present this card to healthcare  
professionals (doctor, nurse)  
upon consultation  
or hospitalisation.

This card should be folded along the dotted lines

Patient's Name: \_\_\_\_\_

IMLYGIC® Prescriber's (Doctor's) Name: \_\_\_\_\_

Doctor's Phone Number: \_\_\_\_\_

Name of Centre/Institution (if applicable): \_\_\_\_\_

Start Date of IMLYGIC® Treatment: \_\_\_\_\_

IMLYGIC® Batch Numbers	Dates Administered
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

Product Manufacturer and License Holder: \_\_\_\_\_

Version 1.0

December 2015 UKIE-NPC-678x-1115-119411b

# IMLYGIC® ▼

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects talk to your doctor, pharmacist or nurse.

This includes any possible side effects not listed in the package leaflet. See [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) for how to report side effects.

By reporting side effects you can help provide more information on the safety of this medicine. Always provide the batch number from your Patient Alert Card when reporting side effects.

**If you or one of your close contacts develops a herpetic lesion (for example cold sore), please call the doctor (name and phone number provided on front).**

Following treatment, cold sores are common and the lesion can be tested to determine if it is caused by IMLYGIC®. IMLYGIC® is sensitive to the antiviral drug acyclovir and a possible infection can be treated with this drug as determined by your doctor.

**You can get more information from:**

IMLYGIC® Package Leaflet and Patient Safety Brochure available from your doctor, online at <http://www.medicines.org.uk/emc/> or via Amgen Medical Information on 01223 436441 or at [gbinfoline@amgen.com](mailto:gbinfoline@amgen.com)

**INSTRUCTIONS TO PROVIDER:**

A new card is to be completed with the first administration of IMLYGIC®. Record the batch number for every administration of IMLYGIC® on this card. Please supply a new card to the patient if needed during treatment.

**INFORMATION FOR HEALTHCARE PROFESSIONALS:**

IMLYGIC® Summary of Product Characteristics is available online at <http://www.medicines.org.uk/emc/>